Freidel Ninon, Kreuder Liliane, Rabinovitch Brenden Samuel, Chen Frank Yizhao, Huang Ryan S T, Lewis Evan Cole
Department of Clinical Research, Numinus Toronto, Toronto, ON, Canada.
Department of Neuroscience, University of British Columbia Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada.
Front Pharmacol. 2024 Jan 12;14:1326815. doi: 10.3389/fphar.2023.1326815. eCollection 2023.
Psychedelic compounds have been utilized by humans for centuries for medicinal, religious, and tribal purposes. Clinical trial data starting from the early 2000s and continuing today indicates that psychedelics are a clinically efficacious treatment for a variety of neurological and psychiatric disorders. However, all clinical trials examining these substances have excluded any individual with a past or current history of seizures, leaving a large cohort of epilepsy and non-epilepsy chronic seizure disorder patients without anywhere to turn for psychedelic-assisted therapy. These exclusions were made despite any significant evidence that clinically supervised psychedelic use causes or exacerbates seizures in this population. To date, no clinical trial or preclinical seizure model has demonstrated that psychedelics induce seizures. This review highlights several cases of individuals experiencing seizures or seizure remission following psychedelic use, with the overall trend being that psychedelics are safe for use in a controlled, supervised clinical setting. We also suggest future research directions for this field.
几个世纪以来,迷幻化合物一直被人类用于医疗、宗教和部落目的。从21世纪初至今的临床试验数据表明,迷幻剂是治疗多种神经和精神疾病的一种临床有效疗法。然而,所有研究这些物质的临床试验都排除了有癫痫发作既往史或当前病史的任何个体,使得大量癫痫和非癫痫慢性癫痫发作障碍患者无处寻求迷幻剂辅助治疗。尽管没有任何重要证据表明在临床监督下使用迷幻剂会导致或加剧该人群的癫痫发作,但仍有这些排除规定。迄今为止,没有临床试验或临床前癫痫发作模型表明迷幻剂会诱发癫痫发作。本综述重点介绍了几例在使用迷幻剂后出现癫痫发作或癫痫缓解的个体案例,总体趋势是迷幻剂在受控、监督的临床环境中使用是安全的。我们还提出了该领域未来的研究方向。